The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B
Open accessAbstract
BACKGROUND: We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. METHODS: Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. RESULTS: During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. CONCLUSIONS: In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy. This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine (Section 7.1) and troglitazone (Section 7.4) are intrinsic toxicodynamic failures, driven by human-relevant mitochondrial injury and reactive-metabolite formation, respectively.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fialuridine, an antiviral nucleoside analogue, caused catastrophic hepatic failure and lactic acidosis in a 1993 clinical trial, resulting in five deaths and two liver transplantations.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies across multiple species showed no indication of the severe mitochondrial toxicity observed in humans, because fialuridine’s incorporation into mitochondrial DNA is mediated by a human-specific mitochondrial transporter [69,70].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fourth, idiosyncratic toxicities, such as those underlying the fialuridine and troglitazone failures, are by definition not captured by any pharmacokinetic scaling framework, and even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“even sophisticated PBPK or PBPK–PD models cannot reliably anticipate them without orthogonal mechanistic assays [69,70,75,76]”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [69]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Even a pilot study on 43 patients treated for 2 and 4 weeks duration with Fialuridine did not reveal any signs of hepatic toxicity on initial examination.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“During 13th week of phase II studies, one of the patients suddenly developed hepatic toxicity and lactic acidosis. At this point, trial was stopped for all other patients.”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Even after discontinuation of Fialuridine administration, seven other patients showed signs of severe hepatic toxicity five of which could not survive and other two could survive only after liver transplantation.[17]”
From TGN1412: From Discovery to Disaster (2010) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, D., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 974
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K. L., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C. H., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 838
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
Dalakas, M. C., Illa, I., Pezeshkpour, G. H., Laukaitis, J. P., Cohen, B. H., & Griffin, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004193221602 · Cited by 837
Doong, S.-L., Tsai, C. H., Schinazi, R. F., Liotta, D. C., & Cheng, Y. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8495 · Cited by 513
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
Arnaudo, E., Shanske, S., DiMauro, S., Schon, E. A., Moraes, C. T., Schon, E. A., & Dalakas, M. C. (1991) · The Lancet · doi:10.1016/0140-6736(91)91294-5 · Cited by 504
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
Hoofnagle, J. H., Peters, M. G., Mullen, K. D., Jones, D. B., Rustgi, V. K., Bisceglie, A. M. D., Hallahan, C. W., Park, Y., Meschievitz, C., & Jones, E. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90367-8 · Cited by 420
Self-citationReversal of Fulminant Hepatic Failure Using An Extracorporeal Liver Assist Device
Sussman, N., Chong, M. G., Koussayer, T., He, D.-E., Shang, T. A., Whisennand, H. H., & Kelly, J. H. (1992) · Hepatology · doi:10.1002/hep.1840160112 · Cited by 341
Chen, C., Vazquez-Padua, M. A., & Cheng, Y. C. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11067-5 · Cited by 296
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S.-F., Wu, P., Lai, C., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 239
Hodge, R. A. V., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 207
Research works printed but not linked: 7
- Dusheiko G, Hoofnagle JH. Hepatitis B. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford textbook of clinical hepatology. New York: Oxford University Press, 1991:571-92.
- Paar DP, Hooten TM, Smiles KA, et al. The effect of FIAU on chronic hepatitis B virus (HBV) infection in HIV-infected subjects (ACTG 122b). In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Calif., October 10–14, 1992. Washington, D.C.: American Society for Microbiology, 1992:264. abstract.
- 10.1002/hep.1840160402 · DOI
- Stevenson W, 1995, Transplant Proc, 27, 1219
- Chen CH, 1991, Mol Pharmacol, 39, 625
- Klecker RW, 1994, Mol Pharmacol, 46, 1204
- Maxson CJ, 1992, Am J Gastroenterol, 87, 708
Cited by
Sorted by citations
Items 501–600 of 614
Bueno, C. O. P., Saldarriaga, C., Roncancio-Villamil, G., & Barreneche, M. F. Á. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7749 · Cited by 2
Corydalis and Drug-Induced Liver Injury: A Series of 2 Cases
Engman, S., Puello, F., Khoury, K., Miller, D. M., Isidan, K., & Shah, D. A. (2023) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001230 · Cited by 2
Davies, S. E. (1997) · Current Diagnostic Pathology · doi:10.1016/s0968-6053(05)80003-1 · Cited by 2
Yu, F. (2014) · Journal of Molecular Pharmaceutics & Organic Process Research · doi:10.4172/2329-9053.1000112 · Cited by 2
Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.
Sw, H., & Leo, Y. S. (2001) · PubMed · Cited by 2
Drug-Induced Fatty Liver Disease
Samala, N. R., & Chalasani, N. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0418-6 · Cited by 2
Shapiro, J. M., & Braun, N. M. T. (1999) · Journal of Intensive Care Medicine · doi:10.1046/j.1525-1489.1999.00275.x · Cited by 2
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_7 · Cited by 2
Simone, C. D., Moretti, S., Marcellini, S., Trinchieri, V., Boschini, A., & Famularo, G. (1997) · Springer eBooks · doi:10.1007/978-1-4615-6005-0_11 · Cited by 2
Treatment of Chronic Hepatitis B and Chronic Hepatitis C
Terrault, N. A. (1996) · Reviews in Medical Virology · doi:10.1002/(sici)1099-1654(199612)6:4 · Cited by 2
Pharmacological Management of Chronic Viral Hepatitis
Lam, N. P. (1998) · Journal of Pharmaceutical Care in Pain & Symptom Control · doi:10.1300/j088v06n03_04 · Cited by 2
Principles of clinical pharmacology in postexposure prophylaxis
Flexner, C. W. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00058-2 · Cited by 2
Sheu, M., Lin, C., Sun, C., Kuo, H., Koay, L., Lee, C., Chen, J.-J., Tang, L., & Tsai, S. (2006) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60155-8 · Cited by 2
Larson, A. A., & Sokol, R. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108918978.035 · Cited by 2
Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation
Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2
Tran, A. T., Crawford, J. J., Mandal, D., Güney, T., & Karmel, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch19 · Cited by 1
Holm, C., Finelli, J. F., Frare, M. F., Armento, A., & Ayehunie, S. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1574387 · Cited by 1
Friedrich, V. D., Neier, K. E., Müller, K., Fogal, B., Loncová, Z., Rade, M., Shoaib, M., Koehl, U., Hoyt, K., Pande, P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603716 · Cited by 1
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Scheeff, S., Arakelyan, J., & NG, B. K. W. (2026) · Israel Journal of Chemistry · doi:10.1002/ijch.70017 · Cited by 1
Organoids: From Bench to Bedside Applications
Li, K., Cao, R., Li, M., Tian, Z., Fan, H., Hong, B., & Liu, X. (2026) · MedComm · doi:10.1002/mco2.70768 · Cited by 1
Firoozbakht, F., Wenke, N. K., Tsoy, O. V., Loscalzo, J., Baumbach, J., & Elkjaer, M. L. (2025) · npj Drug Discovery. · doi:10.1038/s44386-025-00021-6 · Cited by 1
Coghlan, H., Regan, S., Chouhan, B., Williams, D. P., Sison-Young, R., Jones, A. R., & Copple, I. M. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag061 · Cited by 1
High-yield isolation of primary human hepatocytes from small liver samples
Guy, T., Ruan, J.-L., Lee, C., Purdie, K., Johnson, D. R., Gordon-Weeks, A. N., & Nanchahal, J. (2025) · In vitro models · doi:10.1007/s44164-025-00097-4 · Cited by 1
Relevance of reactive metabolites and covalent binding to drug candidate selection
Uetrecht, J. (2026) · Drug Metabolism Reviews · doi:10.1080/03602532.2026.2620682 · Cited by 1
Yen, T.-H., Negi, C. K., Sakolish, C., Baker, E. S., & Rusyn, I. (2026) · Toxicology in Vitro · doi:10.1016/j.tiv.2026.106290 · Cited by 1
Cardiotoxicity and HIV/AIDS Therapy
Lewis, W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00714-4 · Cited by 1
Optimal dose identification: predicting a safe dose in man from animal studies
Park, B. K., Kitteringham, N. R., Maggs, J. L., Boocock, D. J., White, I. N. H., Elsby, R., & Pirmohamed, M. (2001) · International Congress Series · doi:10.1016/s0531-5131(01)00283-7 · Cited by 1
Antiviral Drug Development: The Road Less Taken
Balfour, H. H. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000910 · Cited by 1
HIV Co-Infection Drug Toxicity
McGovern, B., Sulkowski, M., & Sterling, R. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00038-3 · Cited by 1
Safety and Efficacy Evaluation Using Nonhuman Primates
Clemons, D. J., Meador, V., Weinbauer, G. F., & Wakefield, G. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381365-7.00019-4 · Cited by 1
The Role of Liver Biopsy in Drug-Induced Liver Injury
Kleiner, D. E. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00486-w · Cited by 1
Self-citationGenetically Engineered Animal Models in Toxicologic Research
Himmel, L. E., Wilson, K. L., Santagostino, S. F., & Bolon, B. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00024-8 · Cited by 1
Imaging Virus-Associated Cancer
Fu, D.-X., Foss, C. A., Nimmagadda, S., Ambinder, R. F., & Pomper, M. G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404371 · Cited by 1
Treatment of HBV-Related Liver Disease in the Dialysis Population: Reality and Promises
Fabrizi, F., Lunghi, G., & Martin, P. B. (2001) · The International Journal of Artificial Organs · doi:10.1177/039139880102400906 · Cited by 1
Goldman, S. A. (2016) · Drug Safety · doi:10.1007/s40264-016-0442-9 · Cited by 1
Straus, S. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00011-3 · Cited by 1
Self-citationUnanticipated Risk in Clinical Research
Straus, S. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382167-6.00010-2 · Cited by 1
Self-citationLiver Injury Due to Drugs and Herbal Agents
Kleiner, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-42873-6.00023-8 · Cited by 1
Self-citationMitochondrial functionalism in HIV-infected children receiving antiretroviral therapy
Núñez, C. M. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Idiosyncratic Drug Reactions and the Potential Role of Metabolism
Uetrecht, J. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm128 · Cited by 1
Acute Liver Failure and Related Syndromes
Durand, F., & Bernuau, J. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch15 · Cited by 1
Antiviral treatment for chronic hepatitis B.
Lai, C., & Pc, W. (1997) · PubMed · Cited by 1
Application of Pluripotent Stem Cells in Drug‐Induced Liver Injury Safety Assessment
Pridgeon, C. S., Zhang, F., Heslop, J. A., Nugues, C., Kitteringham, N. R., Park, B. K., & Goldring, C. E. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch21 · Cited by 1
Cho, T., & Uetrecht, J. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00436 · Cited by 1
Meinert, C. L. (2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt002 · Cited by 1
BATE, R. G., & Bollipo, S. J. (1996) · Drug and Alcohol Review · doi:10.1080/09595239600186031 · Cited by 1
Berns, J. S., Cohen, R. M., & Rudnick, M. R. (2003) · Springer eBooks · doi:10.1007/1-4020-2586-6_12 · Cited by 1
Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.035 · Cited by 1
Matthes, E., & Langen, P. (1997) · Springer eBooks · doi:10.1007/978-3-662-08822-7_8 · Cited by 1
Toxicological study of the anti-HBV agent β-L-thymidine
Bridges, E. G., Bryant, M. L., Placidi, L., Faraj, A., Loi, A.-G., Pierra, C., Dukhan, D., Gosselin, G., Imbach, J., Hernandez, B. Y., et al. (2003) · Elsevier eBooks · doi:10.1016/b978-044450986-4/50073-4
15 Medicamenteus-toxisch leverlijden
Fevery, J. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-7437-3_15
Mitochondrial DNA and RNA Polymerases
Yin, Y. W. (2013) · Nucleic acids and molecular biology · doi:10.1007/978-3-642-39796-7_11
C-6 pyrimidine analogs for the PET imaging of HSV1-thymidine kinase expression
Müller, U. (2011) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-007086372
Meanwell, N. A., D’Andrea, S. V., Cianci, C., Dicker, I. B., Yeung, K., Belema, M., & Krystal, M. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch11
Selective targeting of the anti-viral agent lamivudine to the liver
Chimalakonda, K. C. (2007) · ThinkTech (Texas Tech University)
Antiviral Chemotherapy for Viral Hepatitis
O’Brien, C., & Moonka, D. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-702-4_9
Preclinical Antecedents to Early Human Clinical Trials
(2010) · Wiley eBooks · doi:10.1002/9781444318579.ch3
Anti-viral activities of L-nucleosides
Agrofoglio, L. A., & Challand, S. R. (1998) · Springer eBooks · doi:10.1007/978-94-007-0816-7_7
da Silva, G. H., & Escanhoela, C. A. F. (2009) · Revista de Ciências Médicas
Al-Derwish, O. (2008) · Enlighten: Theses (The University of Glasgow)
Sokol, R. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139012102.036
Schmid, M. (2008) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.9270
Sistare, F. D., Devarajan, P., Devarajan, P., & Sistare, F. D. (2015)
Reviewbias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010)
Role of Inflammation in Metabolism and Hepatotoxicity of Prototypical Drugs
Gandhi, A. S. (2012)
The I mpact of Nucleoside Sugar Modific ation on Biochemical DNA Transactions
Williams, A. A. (2012) · The Scholars Repository - LLU (Loma Linda University)
2. Non-clinical Data Needed for the Conduct of Microdose Clinical Study
Ohno, Y. (2009) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.41.9
Interferone und Nukleosidanaloga
Hinrichsen, H. M., & Schmidt, W. E. (1998) · Der Internist · doi:10.1007/s001080050148
Kim, S., Jee, J., & Hong, J. H. (2015) · Journal of the Chosun Natural Science · doi:10.13160/ricns.2015.8.2.99
Madeley, D., & Taylor, C. (1995) · The Lancet · doi:10.1016/0140-6736(95)90026-8
Applications of Substructure-Based SAR in Toxicology
Rosenkranz, H. S., & Thampatty, B. P. (2005) · CRC Press eBooks · doi:10.1201/9780849350351.ch9
Kelly, K. L. (2016) · UA Campus Repository (The University of Arizona)
Zhu, X. (2013) · TSpace (University of Toronto)
Bouter, C. (2017) · Der Nuklearmediziner · doi:10.1055/s-0043-105005
Drugs acting on mitochondrial pathways
Srinivasan, A., Selvarajan, S., Dkhar, S. A., & Gunaseelan, V. (2017) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20174353
Skeletal Muscle Mitochondrial Toxicity
Herbert, E. K., Herbert, S., & Herbert, K. E. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch8 · Cited by 1
Ball, A. L., Kamalian, L., Jolly, C., & Chadwick, A. E. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch6
Predicting Off‐Target Effects of Therapeutic Antiviral Ribonucleosides
Arnold, J. J., & Cameron, C. E. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch26
Human amnion epithelial stem cells as a therapy for liver disease
srinivasan, R. C. (2019) · Figshare
Unanticipated Risk in Clinical Research
Straus, S. E. (2002) · Elsevier eBooks · doi:10.1016/b978-012274065-7/50010-1
Self-citationAngell, R. J., Gorton, M., Memery, J., & White, J. E. (2018) · Routledge eBooks · doi:10.4324/9781315277288-8
Reminiscences of a soon-to-be ex-hepatologist
Sherman, M. (2020) · Canadian Liver Journal · doi:10.3138/canlivj-2020-0021
Modelling and genetic correction of liver genetic diseases
Zabulica, M. (2021) · Figshare
Quantitative Analysis of Intracellular Drug Concentrations in Hepatocytes
Saran, C., Beaudoin, J. J., Pfeifer, N. D., & Brouwer, K. L. R. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_5
Adam, D., Christ, W., Hofmann, D., Kemmler, H. D., Knobloch, J., Lehn, N., Lemmen, S., Lode, H., Mertens, R., Naber, K. G., et al. (2004) · Springer eBooks · doi:10.1007/978-3-642-18577-9_5
Berns, J. S., Doyle, A. M., & Kasbekar, N. (2008) · Springer eBooks · doi:10.1007/978-0-387-84843-3_16
Meinert, C. L. (2005) · Wiley eBooks · doi:10.1002/0470011815.b2a01009
(2002) · CRC Press eBooks · doi:10.1201/9781420032123.ch9
Meulenbelt, J., & FIJEN, J. W. (2007) · Elsevier eBooks · doi:10.1016/b978-0-7216-0693-4.50058-x
von Bruchhausen, F., Hackenthal, E., Ebel, S., Holzgrabe, U., Frahm, A. W., Albinus, M., Amschler, G., Angerer, E. V., Arras-Reiter, Barth, P. J., et al. (1999) · Springer eBooks · doi:10.1007/978-3-642-58387-2_6
Lee, W. M. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch97
Perhaps not everyone knows that …
(1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010477
de Groen, P. C., & LaRusso, N. F. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-726-0_41
Clinical consequences of drug-induced mitochondrial dysfunction
Jensen, R. L., Kiy, R. T., Dayel, F. F. B., & Chadwick, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88462-4.00026-2
The effects of HIV and the antiretrovirals on the mitochondria
Barroso, S. E., & Garrabou, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88462-4.00031-6
He, T., Chen, B., Li, Y., Song, Y., Wu, J., Xiong, B., Wang, B., & Long, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03674-w
Metadata
- Authors
- McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J. L., Straus, S. E., & Hoofnagle, J. H.
- Affiliations
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Cancer Institute (UA)
- University of Virginia Hospital (US)
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1995-10-26
- Volume
- 333
- Issue
- 17
- Pages
- 1099-1105
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2327070670
- Cited by
- 616
- References
- 39
- Citations by year
- 2026: 14 · 2025: 11 · 2024: 17 · 2023: 13 · 2022: 11 · 2021: 19 · 2020: 13 · 2019: 26 · 2018: 32 · 2017: 23 · 2016: 27 · 2015: 16 · 2014: 12 · 2013: 16 · 2012: 10
- FWCI
- 28.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- NIH Clinical Center
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- FIAU, lactic acidosis, liver failure, hepatotoxicity, chronic hepatitis B, nucleoside analogues, drug toxicity, mitochondrial damage, pancreatitis, neuropathy, myopathy, liver transplantation, drug-induced liver injury
- MeSH terms
- Acidosis, Lactic, Adult, Alanine Transaminase, Antiviral Agents, Arabinofuranosyluracil, Chronic Disease, DNA, Mitochondrial, DNA, Viral, Female, Hepatitis B, Humans, Jaundice, Liver, Male, Middle Aged, Pancreatitis, Peripheral Nervous System Diseases, Drugs, Investigational, Liver Transplantation, Liver Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
